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Abstract 
Background: Transfusion-transmitted (TT) malaria is an alternative infection route that has gained little attention 
from authorities, despite representing a life-threatening condition. There has been no systematic review of this health 
problem in American countries. The aim of this study was to describe the clinical and epidemiological characteris-
tics of TT malaria in the Americas and identify factors associated with lethality based on the studies published in the 
literature.
Methods: Potentially relevant papers in all languages were retrieved from MEDLINE and LILACS. Additional articles 
were obtained from reviews and original papers. Publications on screening of candidate blood donors and on surveil-
lance of TT malaria cases were included. Odds ratios with respective 95% confidence intervals (95% CI) were calcu-
lated. Epidemiological characteristics of blood donors of TT malaria cases, including a pooled positivity of different 
tests for malaria diagnosis, were retrieved.
Results: A total of 63 publications regarding TT malaria from seven countries were included, from 1971 to 2016. A 
total of 422 cases of TT malaria were recorded. Most TT malaria cases were in females (62.0%) and 39.5% were in the 
≥61 years-old age group. About half of all cases were from Mexico (50.7%), 40.3% from the United States of America 
(USA) and 6.6% from Brazil. Gyneco-obstetrical conditions (67.3%), surgical procedures (20.6%) and complications 
from neoplasias (6.1%) were the most common indications of transfusion. Packed red blood cells (RBCs) (50.7%) and 
whole blood (43.3%) were the blood products mostly associated with TT malaria. Cases were mostly caused by Plas-
modium malariae (58.4%), followed by Plasmodium vivax (20.7%) and Plasmodium falciparum (17.9%). A total of 66.6% 
of cases were diagnosed by microscopy. Incubation period of 2–3 weeks was the most commonly observed (28.6%). 
Lethality was seen in 5.3% of cases and was associated with living in non-endemic countries, P. falciparum infection 
and concomitant neoplastic diseases.
Conclusion: There is an important research and knowledge gap regarding the TT malaria burden in Latin American 
countries where malaria remains endemic. No screening method that is practical, affordable and suitably sensitive 
is available at blood banks in Latin American countries, where infections with low parasitaemia contribute greatly to 
transmission. Lethality from TT malaria was not negligible. TT malaria needs to be acknowledged and addressed in 
areas moving toward elimination.
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Background
Malaria is an infectious disease caused by parasites of the 
genus Plasmodium that is characterized by a potentially 
fatal acute febrile illness. It is considered a great pub-
lic health problem worldwide. According to the World 
Health Organization (WHO), about 3.2 billion people 
were at risk of developing malaria globally in 2015, with 
212 million new cases and 429,000 deaths estimated [1]. 
Malaria transmission is widespread, with cases concen-
trated mostly in tropical and sub-tropical areas, mainly 
in Central and South America and in Southeast Asia for 
Plasmodium vivax [2] and in Africa for Plasmodium fal-
ciparum [3]. Clinically, malaria can manifest with severe 
symptoms, which can evolve to lethal cases, or present as 
asymptomatic infections. The latter are particularly chal-
lenging in non-endemic settings and those approaching 
elimination, as asymptomatic Plasmodium parasites in 
low densities are still able to transmit infection but less 
likely to be diagnosed.
In the Americas, the population at risk for malaria 
exceeds 120 million in over 21 countries, with P. vivax 
infections accounting for more than 70% of reported 
cases [1]. Only five countries in this region have higher 
than 40% P. falciparum infection rate (Haiti, Dominician 
Republic, Guyana, French Guiana, Suriname). Out of 
390,000 confirmed cases in the Americas in 2015, three 
countries were responsible for more than 75%: Brazil 
(37%), Venezuela (23%) and Colombia (17%) [1]. In Bra-
zil, malaria transmission is mainly restricted to the Ama-
zon region with 99.8% of all reported cases, of which 83% 
are P. vivax malaria [4]. Despite an 80% decline in mortal-
ity over the past 15 years, 79 malaria-related deaths were 
reported in the Americas [1]. Interestingly, the high-
est lethality is seen outside the endemic regions, where 
a higher proportion of P. falciparum combined with late 
diagnosis may lead to higher rates of complications [5].
The natural malaria transmission occurs through 
the blood meal bite of the female Anopheles mos-
quito, although infection may also occur congenitally 
or accidentally, through infected blood transfusion. 
Transfusion-transmitted (TT) malaria is an alterna-
tive infection route that has gained little attention from 
authorities, despite presenting real danger to patients. 
Subjects requiring blood transfusion are a vulnerable 
population in debilitating conditions. Vivax malaria was 
traditionally considered a benign disease with no associ-
ated severe cases. Recent data however, have shown that 
vivax malaria may result in severe disease and death [6–
8] including in the Americas [10–14]. The Brazilian Min-
istry of Health has shown that although the number of 
hospitalizations and severe cases in Brazil has decreased 
in recent years, deaths due to malaria infection still occur, 
with a total of 60 deaths in 2012 and 41 in 2013 [9]. A 
case series of autopsies in which P. vivax was consid-
ered a causative agent or a contributing factor for death 
showed that 13 out of 17 patients presented co-morbid-
ities [15].
Blood banks usually perform a screen of donor candi-
dates’ health before blood donation, including current 
infections and a detailed history of previous diseases and 
travel. The criteria for this haemovigilance are defined 
by each country through their national regulation agen-
cies. In Brazil, policies regarding blood donation dif-
fer between malaria endemic and non-endemic regions. 
In non-endemic areas, candidates will not be accepted 
as donors if they have been to endemic areas within 
the previous 6  months or had malaria in the previous 
3 years, while in areas with active malaria transmission, 
the presence of Plasmodium or plasmodial antigens must 
be tested [16, 17]. A recent study in the Amazon region, 
that evaluated ten blood banks regarding infrastructure 
and procedures relative to TT malaria, found that none 
was classified as ‘adequate’, highlighting an urgent need 
to call attention to this challenge and work towards bet-
ter standardization and regulation compliance regard-
ing TT malaria by authorities [18]. Furthermore, as 
most malaria-infected blood donors are asymptomatic, 
both the use of clinical and epidemiological criteria as 
well as microscopy and rapid diagnostic tests (RDTs) 
are potentially insufficient for malaria screening. These 
asymptomatic infections characterized by low parasite 
densities require more sensitive methods for detection 
[19]. Although cases of TT malaria are assumed based 
on different criteria, transmission can only be proven 
definitely by genotyping. However, most cases in the lit-
erature are “presumed” cases, where genotyping was not 
done or reported.
The primary objective of this study was to describe epi-
demiological characteristics of TT malaria in the Ameri-
cas through a systematic review. Secondary objectives 
included description of donor epidemiology character-
istics, donor selection process in malaria endemic and 
non-endemic regions, diagnostic methods used in donor 
screening, and demographical, clinical and laboratory 
characteristics of TT malaria.
Methods
A systematic review was conducted of all available arti-
cles regarding TT malaria in countries of the Americas. 
Potentially relevant articles in English, Spanish and Por-
tuguese were accessed from MEDLINE and LILACS to 
review their full texts. A free text search using the com-
bination of Medical Subject Heading (MeSH) terms and 
keywords was utilized (Table  1). Only original research 
was included. Studies were eligible for inclusion if they 
reported any information on TT malaria in subjects 
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living in American countries. An individual was con-
sidered to have malaria if they presented with a positive 
diagnostic test, such as microscopy, direct serology, RDT, 
or DNA amplification tests. Moreover, positive indirect 
serology was considered a marker of lifetime Plasmo-
dium infection [4]. After eliminating duplicates, relevant 
papers were identified by screening titles and abstracts. 
Two independent investigators performed the selection, 
with disagreements being included after consensus was 
reached. Citation tracking of reviews and original papers 
resulted in inclusion of additional articles. Data were 
extracted by filling out a template with study area, study 
design, participant characteristics, number of cases, diag-
nostic methods, and Plasmodium species. Afterwards, 
articles were classified in the following categories:
Epidemiological screening of candidate blood donors
Cross-sectional information from donations deferral 
based on epidemiological history was collected, including 
country and city of the study, time period, subjects char-
acteristics, sample size, and deferral causes and rates.
Laboratorial screening of candidate blood donors
Plasmodium infection prevalences were collected from 
different study areas, including sample size and charac-
teristics, laboratory method employed and prevalence 
rates by species.
Case reports of TT malaria
In this category, data extraction was performed at indi-
vidual level to identify the profile of TT malaria cases, 
including country of the report, gender, age, transfusion 
indication, blood product associated with TT malaria, 
Plasmodium species, method employed for malaria diag-
nosis, incubation period, and signs and symptoms pre-
sented by the patient.
Proportions of deaths from the pooled TT malaria 
cases were compared by Chi square test (corrected by 
Fisher’s test if needed), using living in an endemic coun-
try, gender, age group, transfusion indication, blood 
product associated with TT malaria, Plasmodium spe-
cies, and incubation period as independent variables. 
Odds ratio (OR) with its 95% confidence interval (95% 
CI) was calculated for each association. Where zeros 
caused problems with computation of the OR and 95% 
CI, 0.5 was added to all cells [20, 21]. Statistical analysis 
was performed using STATA package version 14.1 (Stata 
Corp. 2013).
Epidemiological characteristics of blood donors of TT 
malaria cases were retrieved, including gender, age, his-
tory of living or travelling to endemic areas, probable site 
of infection, history of previous episodes of malaria, Plas-
modium species found and detection methods evidenc-
ing Plasmodium infection. Positivities of different tests 
for malaria diagnosis in blood donors were presented.
Results
Study characteristics
An initial database search returned 257 records from 
MEDLINE and 50 from LILACS. After duplicate 
removal, 293 studies were assessed for inclusion criteria 
compliance. Screening by titles and abstracts revealed 68 
potential inclusions. After full text reading, 30 articles 
were removed. Finally, 25 additional records were identi-
fied through manual search of reference lists. A total of 
63 records referred to TT malaria in the Americas and 
were retrieved for inclusion (Fig. 1). From these, 53% (34) 
were from the United States of America (USA), 18% (11) 
from Brazil, 8% (five) from Canada, 8% (five) from Vene-
zuela, 6% (four) from Colombia, 5% (three) from Mexico, 
and 2% (one) from Peru. A total of 11 studies of epidemi-
ological screening of candidate blood donors, 15 studies 
of laboratorial screening of candidate blood donors and 
41 studies reporting TT malaria cases were retrieved.
Candidate blood donor malaria‑related deferrals
Donor selection based on clinical and epidemiologi-
cal profile was described in 11 records, with five from 
the USA, three from Canada, two from Brazil, and one 
from Colombia [22–32] (Table  2). In general, travel or 
residence in malaria-endemic countries, irrespective of 
time, were considered as deferral causes in non-endemic 
countries. In the USA, data indicated a national deferral 
rate of 1.1% due to presumed malaria exposure of among 
Table 1 Keywords and MESH headings used for literature searches
Database Search strategy
LILACS (Transfusion) AND (malaria OR plasmodium)
Medline (Transfusion) AND (malaria OR plasmodium) AND (Antilles OR Latin America OR South America OR Central America OR Caribbean OR 
Anguilla OR Antigua OR Aruba OR Barbuda OR Argentina OR Bahamas OR Barbados OR Belize OR Bolivia OR Brazil OR Chile OR Colom-
bia OR Costa Rica OR Dominica OR Dominican Republic OR Ecuador OR El Salvador OR Grenada OR Grenadines OR Guadeloupe OR 
Guatemala OR Guyana OR Haiti OR Honduras OR Jamaica OR Martinique OR Mexico OR Montserrat OR Nevis OR Nicaragua OR Panama 
OR Paraguay OR Peru OR Puerto Rico OR Saint Kitts OR Saint Lucia OR Saint Vincent OR Suriname OR Surinam OR Trinidad OR Tobago 
OR Uruguay OR Venezuela OR North America OR USA OR Canada)
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28,933,936 candidate blood donors, from 2000 to 2006 
[24], although rates varied between States. In 2006, travel 
to malaria-endemic countries was responsible for 16.2% 
of deferrals of blood donors in six blood centres located 
in San Francisco, Milwaukee, Cincinnati, Pittsburgh, 
Dedham, and Douglasville [30]. Of this group, 42% were 
deferred due to travel to low-risk malaria regions in 
Mexico [31]. In Canada, 7216 donations were deferred 
due to travel to malaria-endemic countries in 2002 [28]. 
Nationwide data from Canada estimated a deferral rate of 
3% among candidate donors from July to December 2004 
[25] and of 4.7% among candidate donors from 2007 to 
2012 [26].
Malaria deferral practices were not consistent among 
endemic countries (Table  2). In Brazil, previous history 
of malaria, travel to endemic areas without prophylaxis 
in the last 6  months, living in malaria-endemic areas, 
travel to endemic area in the last 6 months, and previous 
malaria in the last year or fever in the last 30 days were 
considered as deferral causes, depending on the location 
where the candidate was tested [27, 32]. In São Paulo, 
a non-endemic area, subjects with history of travel to 
endemic areas without prophylaxis in the last 6 months, 
living in malaria-endemic areas (deferral for 3  years) 
and previous malaria were considered non-eligible for 
blood donations, resulting in a 3% deferral rate [27]. In 
malaria-endemic areas of the Brazilian Amazon, deferral 
donation rates ranged from no deferrals among 31 can-
didates in the State of Mato Grosso, using fever in the 
last 30 days as the deferral reason in a hyperendemic area 
[27], to 11.7% in Manaus where all candidates reporting 
a previous episode of malaria were deferred [32]. In one 
report from Colombia, travel or living in endemic areas 
in the last year was considered as a deferral cause, result-
ing in a deferral rate in Cali of 40.2% (115) in 2002 in a 
group of 286 candidate donors [22].
Fig. 1 Flow chart of inclusion. Four articles presented more than one type of study category































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 6 of 14Alho et al. Malar J  (2017) 16:78 
Plasmodium screening of candidate blood donors
Laboratory testing of blood donors (12,370 subjects), 
deferred donors (5696 subjects) or blood donors sus-
pected to be responsible for TT malaria cases (47 
subjects) was shown in 15 studies from Brazil (nine 
locations), USA (two locations), Venezuela (six loca-
tions), and Colombia (two locations) (Table  3). Among 
selected blood donors, microscopy was used for screen-
ing in seven locations, all with negative results. RDT was 
used in only one study, with no infections detected [33]. 
PCR was used for donor screening in nine locations, with 
results ranging from 0.0% in Cali (Colombia) [22] and 
USA donors [34] to 7.5% in São Paulo [35]. Compared 
to microscopy, PCR presented higher positivity in one 
study [32] and total agreement in another [36]. Quan-
titative buffy coat was employed in two studies with 
no cases detected [27, 32]. Direct serological tests pre-
sented prevalences of 0.0% in São Paulo, Pará and Mato 
Grosso states (Brazil) [27] and Cali (Colombia) [22] and 
2.4% in Venezuela [36]. In endemic countries, indirect 
serological tests showed prevalences ranging from 0% 
in hypoendemic areas of Colombia [22] and Venezuela 
[37] to 64.5% among blood donors of Mato Grosso (Bra-
zil) [27]. In general, serological screening using indirect 
methods showed circulating anti-Plasmodium antibodies 
with prevalences around 1–2% in non-endemic or hypo-
endemic areas of Latin America [27, 37–39] and higher 
than 10% in malaria-endemic areas [27, 40, 41]. High 
prevalences of both P. falciparum and P. vivax antibodies 
in endemic areas were found with these methods [27, 41].
In Brazil, reports using PCR showed P. falcipa-
rum infections in 5.1% of São Paulo blood donors [35], 
whereas P. vivax was found in 2.3% of blood donors in 
São Paulo [35], 1.3% of blood donors in Belém [42], and 
0.3% of blood donors in Manaus [32]; mixed P. falcipa-
rum–P. vivax infections were found in five locations [35, 
43]. Among malaria-deferred blood donations, micros-
copy and PCR tested negative for all samples in the USA 
[34] and Brazil [32]. Quantitative buffy coat was posi-
tive in a sample from Manaus for which PCR was nega-
tive [32]. Direct serological tests were negative in São 
Paulo and Pará states (Brazil) [27]. Indirect serological 
tests showed a prevalence of 1.6% among 5610 malaria-
deferred donors in the USA [34].
In the USA, blood donors suspected to be sources for 
TT malaria cases tested positive for P. falciparum (12.8%) 
and P. malariae (6.3%) using indirect serology [44].
Epidemiological and clinical profile of TT malaria patients
This systematic review retrieved 422 cases of TT malaria 
(Table 4). Cases were mostly reported from Mexico (214 
cases; 50.7%), the USA (170 cases; 40.3%) and Brazil (28 
cases; 6.6%). Most cases were female (62.0%) or belonged 
to the group age ≥61 years old (39.5%). Gyneco-obstet-
rical conditions (67.3%), surgical procedures (20.6%) 
and complications from neoplasias (6.1%) were the most 
common indications of transfusion. Packed red blood 
cells (RBCs) (50.7%), whole blood (43.3%) and plate-
lets (6.0%) were the blood products associated with 
TT malaria. Cases were mostly caused by P. malariae 
(58.4%), P. vivax (20.7%) and P. falciparum (17.9%). A 
total of 66.6% of the cases were diagnosed by microscopy 
and 30.6% by microscopy plus indirect immunofluores-
cence (IIF). The incubation period was reported in only 
10% of all cases, from which 2–3 weeks was the most fre-
quent (28.6%), with 61.9% of cases showing an incubation 
period of 2–5 weeks.
Fever (99.3%) and chills (69.2%) were the most com-
mon signs of malaria presented by the TT malaria cases. 
Signs and symptoms of severe malaria, such as haemo-
globin drop, jaundice, convulsions, hypotension, renal 
failure, respiratory failure, and disseminated intravascu-
lar coagulation were also reported. Lethality was 5.3%.
Risk factors for lethality among TT malaria patients
Living in an endemic country was associated with a lower 
odd of lethality from TT malaria [OR 0.19 (95% CI 0.06–
0.54); (p  =  0.002)]. Regarding background conditions, 
neoplasias were associated with a higher odd of lethality 
from TT malaria in comparison with other transfusion 
indications [OR 0.02 (95% CI <0.01–0.51); (p =  0.018)]. 
Plasmodium falciparum malaria was associated with a 
higher risk of lethality in comparison with P. malariae 
[OR 6.72 (95% CI 2.36–19.13); (p < 0.001)] and P. vivax 
[OR 7.26 (95% CI 1.49–35.41); (p = 0.014)]. Gender, age, 
blood product received and incubation period were not 
associated with lethality from TT malaria (Table 5).
Characteristics of donors identified as responsible for TT 
malaria cases
Epidemiological characteristics of 163 blood donors 
identified as responsible for TT malaria cases are pre-
sented in Table  6. Completeness of individual informa-
tion ranged from 10.4% for age to 82.2% for method 
evidencing Plasmodium infection. Blood donors were 
mostly male (81.6%) and between 21 and 30  years old 
(52.9%). History of living or travelling to endemic areas 
was reported by 96.8% of the donors. Probable site of 
infection was reported mostly as Sub-Saharan Africa 
(61.0%), including Nigeria (18.6%), Ghana (10.2%) and 
Liberia (10.2%). Latin American countries were identified 
as the probable site of infection for 15.3% of the donors: 
Central American countries (5.1%), the Brazilian Atlantic 
coast (3.4%) and Mexico (3.4%). Mediterranean countries 
(11.9%), Vietnam (8.5%) and India (3.4%) were also iden-
tified as probable sites of infection. History of previous 
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Table 3 Malaria prevalence in candidate blood donors in the American continent
Study area Sample size and fea‑
tures
Detection method Prevalence (%) Prevalence by species 
(%)
Reference
Manaus, Brazil 407 blood donors Microscopy 0.0 – Torres et al. [33]
RDT 0.0 –
São Paulo, Brazil 1108 blood donors PCR 7.5 P. falciparum (5.1) Maselli et al. [35]
P. vivax (2.3)
Mixed P. falciparum–P. 
vivax infection (0.1)
USA 5610 malaria-deferred 
donors
EIA 1.6 NA Nguyen et al. [34]
PCR 0.0 –
Pará, Brazil 595 blood donors PCR 1.3 P. vivax (1.3) Batista-dos-Santos et al. 
[42]
Caracas, Ciudad Bolívar, 
Puerto Ayacucho and 
Cumaná, Venezuela
762 blood donors Direct EIA 2.4 NA Contreras et al. [36]
Microscopy 0.0 –
PCR 0.0 –
Porto Velho (RO), Brazil 100 blood donors PCR 3.0 Mixed P. falciparum–P. 
vivax infection (2.3)
Fugikaha et al. [43]
Macapá (AP), Brazil 100 blood donors PCR 3.0 Mixed P. falciparum–P. 
vivax infection (2.3)
Belém (PA), Brazil 100 blood donors PCR 2.0 Mixed P. falciparum–P. 
vivax infection (2.3)
Rio Branco (AC), Brazil 100 blood donors PCR 1.0 Mixed P. falciparum–P. 
vivax infection (2.3)
Manaus (AM), Brazil 286 blood donors Microscopy 0.0 – Torres et al. [32]
QBC 0.0 –
PCR 0.3 P. vivax (0.3)
Manaus (AM), Brazil 38 deferred donations Microscopy 0.0 – Torres et al. [32]
QBC 1.4 NA
PCR 0.0 –
Caracas, Venezuela 500 blood donors IIF (IgG Pf ) 0.8 P. falciparum (0.8) Contreras et al. [39]
ELISA (IgG Pf ) 0.8 P. falciparum (0.8)
Ciudad Bolívar, Venezuela 500 blood donors IIF (IgG Pf ) 3.8 P. falciparum (3.8) Contreras et al. [39]
ELISA (IgG Pf ) 2.0 P. falciparum (2.0)
Cali, Colombia 286 blood donors Microscopy 0.0 – Castillo and Ramírez [22]
EIA IgG 0.0 –
EIA HRPII 0.0 –
PCR 0.0 –
São Paulo (SP), Brazil 1164 blood donors Microscopy 0.0 – Sáez-Alquézar et al. [27]
DIF 0.0 –
IIF IgG anti-Pv – P. vivax (1.2)
IIF IgG anti-Pf – P. falciparum (0.9)
ELISA IgG Pf – P. falciparum (1.0)
36 deferred donations Microscopy 0.0 –
DIF 0.0 –
IIF IgG anti-Pv – P. vivax (16.7)
IIF IgG anti-Pf – P. falciparum (5.6)
ELISA IgG Pf – P. falciparum (2.7)
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episodes of malaria was reported for 33.3% of the donors. 
Plasmodium species found in donors were mostly P. falci-
parum (43.1%), P. malariae (27.7%) and P. vivax (23.1%). 
A total of 49.3% of donors were diagnosed by IIF alone 
and 33.6% by microscopy plus IIF.
Positivities of PCR, microscopy and IIF for malaria 
diagnosis in blood donors were 73.3, 79.7 and 100.0%, 
respectively. PCR positivity ranged from 62.5% for P. 
falciparum to 100.0% for P. vivax. Microscopy positivity 
ranged from 66.7% for P. ovale to 90.0% for P. vivax.
Discussion
International policies recommend that blood for trans-
fusion should be screened for TT infections, including 
malaria [45], however these practices vary considerably 
between countries and regions. Furthermore, there has 
been a paucity of information concerning the distribu-
tion and potential role of different Plasmodium species in 
transfusion-related malaria cases, and the clinical impact 
of parasitaemic blood amongst patients with co-morbid-
ities, which most of blood transfusion recipients present 
Table 3 continued
Study area Sample size and fea‑
tures
Detection method Prevalence (%) Prevalence by species 
(%)
Reference
Belém (PA), Brazil 238 blood donors Microscopy 0.0 – Sáez-Alquézar et al. [27]
QBC 0.0 –
DIF 0.0 –
IIF IgG anti-Pv – P. vivax (9.6)
IIF IgG anti-Pf – P. falciparum (10.1)
ELISA IgG Pf P. falciparum (17.2)
12 deferred donations Microscopy 0.0 –
QBC 0.0 –
DIF 0.0 –
IIF IgG anti-Pv – P. vivax (25.0)
IIF IgG anti-Pf – P. falciparum (41.6)
ELISA IgG Pf P. falciparum (25.0)
Matupá and Peixoto de 
Azevedo (MT), Brazil
31 blood donors Microscopy 0.0 –
DIF 0.0 –
IIF IgG anti-Pv – P. vivax (74.2)
IIF IgG anti-Pf – P. falciparum (64.5)
ELISA IgG Pf – P. falciparum (54.8)
Porto Velho (RO), Brazil 230 blood donors IIF IgG Pf – P. falciparum (32.0) Ferreira et al. [41]
IIF IgG Pv – P. vivax (24.0)
IIF IgM Pf – P. falciparum (4.0)
IIF IgM Pv – P. vivax (1.0)
Caracas (DF), Venezuela 426 blood donors EIA IgG Pf – P. falciparum (0.0) Nunez et al. [37]
Cumaná (Sucre), Ven-
ezuela
120 blood donors EIA IgG Pf – P. falciparum (2.5) Nunez et al. [37]
Barcelona (Anzoátegui), 
Venezuela
285 blood donors EIA IgG Pf – P. falciparum (0.7) Nunez et al. [37]
San Fernando (Apure), 
Venezuela
59 blood donors EIA IgG Pf – P. falciparum (1.7) Nunez et al. [37]
Cali, Colombia 1859 blood donors EIA IgG Pf – P. falciparum (13.4) de Morales et al. [40]
Bogotá, Colombia 3114 blood donors EIA IgG Pf – P. falciparum (0.9) de Morales and Espinal 
[38]
USA 47 (from 117) blood 
donors suspected to be 
responsible for 10 TTM 
cases
IIF Ig anti-Pf+Pv+Pm 19.1 P. falciparum (12.8) Sulzer and Wilson [44]
P. malariae (6.3)
P. vivax (0.0)
DIF direct immunofluorescence, EIA enzyme immunoassay, IIF indirect immunofluorescence, NA non-available information, PCR polymerase chain reaction, QBC 
quantitative buffy coat, RDT rapid diagnostic test, USA United States of America
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[19]. This analysis shows that malaria screening in blood 
services in the American continent is mainly based on 
the epidemiological history of the donor. Recent travel or 
residence in malaria-endemic countries was considered 
as deferral causes in the USA and Canada. In areas with 
low odds of donors carrying malaria parasites, exclusion 
of malaria based on history of recent travel or residence 
in malaria-endemic countries [24, 26] seems a reasonable 
approach, as it would not greatly impact the amount of 
blood available for transfusion. In contrast, in some Latin 
American areas, rejection of malaria-positive donors 
would jeopardize the blood supply.
In Latin American countries, there is a knowledge gap 
regarding malaria-deferral practices. In Brazil, previ-
ous history of malaria or fever, and travel to or living in 
endemic areas (with variable time frames), are used as 
deferral causes. However, evidence-based information is 
required to guide malaria screening in these areas, espe-
cially in those with active malaria transmission, in order 
to prevent TT malaria and warrant blood availability for 
transfusion. The wide variation in malaria prevalence in 
candidate donors from dissimilar endemic areas means 
that epidemiological and laboratorial screening poli-
cies need to be adapted locally. In Brazil, epidemiologi-
cal screening is based on annual parasite index (API), 
an indicator not uniform throughout a spatial unit and 
with considerable changes over time [19]. Strikingly, 
this screening strategy does not consider that asympto-
matic P. vivax or P. ovale relapses may occur even several 
months after the primary episode [46]. Cryptic P. malar-
iae and P. falciparum infections [47–50] are also clearly 
related to TT malaria in non-endemic areas from asymp-
tomatic individuals returning years after visiting or liv-
ing in active transmission settings, as shown here for the 
Americas and previously in a review of TT P. falciparum 
infections in non-endemic countries in Europe and the 
Americas (Canada and the USA) [51]. In Latin America, 
malaria is becoming a disease of peri-urban areas, poten-
tially leading to more donations from Plasmodium carri-
ers [19].
Table 4 Epidemiological characteristics of  422 transfu-






Country (n = 422; completeness = 100.0%)
 Mexico 214 50.7
 USA 170 40.3
 Brazil 28 6.6
 Canada 4 0.9
 Venezuela 3 0.7
 Peru 2 0.5
 Colombia 1 0.3
Gender (n = 355; completeness = 84.1%)
 Female 220 62.0
 Male 135 38.0
Age groups (years) (n = 43; completeness = 10.2%)
 ≤5 2 4.7
 6–15 2 4.7
 16–30 8 18.6
 31–45 4 9.3
 46–60 10 23.2
 ≥61 17 39.5
Transfusion indication (n = 165; completeness = 39.1%)
 Gyneco-obstetrical conditions 111 67.3
 Surgical procedures 34 20.6
 Complications from neoplasias 10 6.1
 Haemoglobinopathies 2 1.2
 Nephropathy-associated anaemia 2 1.2
 Other causes of anaemia 6 4.4
Blood product associated with TTM (n = 150; completeness = 35.5%)
 Packed RBCs 76 50.7
 Whole blood 65 43.3
 Platelets 9 6.0
Plasmodium species (n = 392; completeness = 92.9%)
 Plasmodium malariae 229 58.4
 Plasmodium vivax 81 20.7
 Plasmodium falciparum 70 17.9
 Plasmodium ovale 11 2.8
 Mixed P. falciparum–P. vivax 1 0.2
Method(s) employed for malaria diagnosis (n = 314; complete-
ness = 74.4%)
 Microscopy 209 66.6
 Microscopy plus IIF 96 30.6
 Microscopy plus PCR 5 1.6
 Microscopy plus bone marrow aspirate 
examination
2 0.6
 Microscopy plus PCR plus IIF 1 0.3
 PCR 1 0.3
Incubation period (in weeks) (n = 42; completeness = 10.0%)
 ≤2 3 7.1






 3–4 6 14.3
 4–5 8 19.0
 5–6 1 2.4
 6–7 2 4.8
 7–8 7 16.7
 >8 3 7.1
RBCs red blood cells, IIF indirect immunofluorescence, PCR polymerase chain 
reaction
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A major concern in TT malaria epidemiology is to esti-
mate the real burden of Plasmodium infection among 
candidate donors using sensitive detection techniques. 
Currently there is no available assay to screen blood with 
low parasitaemia that is sensitive, practical and affordable 
enough for use by transfusion services [52]. Microscopy 
is time consuming and certainly not the best diagnostic 
tool for asymptomatic donors due to its low sensitivity. 
Rapid diagnostic tests, although faster and reliable, do 
not offer a substantial improvement in sensitivity com-
pared to microscopy [33].
PCR in donor candidates has shown results ranging 
from 0% in Manaus [33] to an unexpected frequency of 
7.5% in São Paulo [35]. The latter finding shall be taken 
with caution since it is in disagreement with other pub-
lications and possibly overestimates the actual risk of 
malaria transmission by blood transfusion in the city of 
São Paulo [53]. Pooled analysis showed that PCR did not 
substantially increase malaria diagnosis in the identified 
blood donors compared to microscopy. Only one study 
suggested PCR as a more sensitive tool to detect low par-
asitaemias in blood donors in the Amazon compared to 
microscopy [32]. Newer techniques such as nucleic acid 
testing (NAT) and loop-mediated isothermal amplifica-
tion (LAMP) would be the best options today in blood 
banks [54]. Recently, increased PCR diagnostic sensitivity 
was achieved by targeting multi-copy genomic sequences 
[55] and by increasing the volume of blood for DNA 
extraction [56]. Serological markers remain positive for 
many years after an initial infection, presenting low spec-
ificity in endemic areas. Indeed, indirect serological tests 
showed high prevalences of P. falciparum and P. vivax 
Table 5 Factors related to death from transfusion-transmitted malaria in the American continent
Variable Death (number, %) Discharge (number, %) OR (95% CI) p
Living in an endemic country
 Yes 5 (27.8) 215 (67.4) – 1
 No 13 (72.2) 104 (32.6) 0.19 (0.06–0.54) 0.002
Sex
 Male 5 (83.3) 16 (43.2) – 1
 Female 1 (16.7) 21 (56.8) 6.56 (0.70–61.86) 0.100
Age group (in years)
 >60 2 (50.0) 8 (21.6) – 1
 31–60 2 (50.0) 6 (16.2) 0.75 (0.068–6.96 0.800
 16–30 0 (0.0) 7 (18.9) 4.41 (0.18–107.29) 0.362
 ≤15 0 (0.0) 16 (43.2) 9.71 (0.42–225.85) 0.157
Transfusion indication
 Gyneco-obstetrical conditions 0 (0.0) 34 (49.3) – 1
 Surgical procedures 5 (62.5) 24 (34.8) 0.06 (0.01–1.22) 0.068
 Complications from neoplasias 2 (25.0) 3 (4.3) 0.02 (<0.01–0.51) 0.018
 Haemoglobinopathies 0 (0.0) 2 (2.9) 0.07 (<0.01–4.48) 0.212
 Nephropathy-associated anaemia 0 (0.0) 2 (2.9) 0.07 (<0.01–4.48) 0.212
 Other causes of anaemia 1 (12.5) 4 (5.8) 0.04 (<0.01–1.24) 0.066
Blood product associated with TT malaria
 Packed RBCs 7 (87.5) 31 (86.1) – 1
 Whole blood 1 (12.5) 4 (11.1) 0.90 (0.09–9.37) 0.932
 Platelets 0 (0.0) 1 (2.8) 0.71 (0.03–19.33) 0.842
Plasmodium species
 Plasmodium falciparum 9 (50.0) 39 (12.4) – 1
 Plasmodium malariae 7 (38.9) 204 (65.0) 6.72 (2.36–19.13) <0.001
 Plasmodium vivax 2 (11.1) 63 (20.1) 7.26 (1.49–35.41) 0.014
 Plasmodium ovale 0 (0.0) 7 (2.2) 3.61 (0.19–68.86) 0.394
 Mixed P. falciparum–P. vivax 0 (0.0) 1 (0.3) 0.72 (0.03–19.14) 0.845
Incubation period (weeks)
 ≤4 16 (89.9) 75 (69.4) – 1
 >4 2 (11.1) 33 (30.6) 3.52 (0.77–16.19) 0.106
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antibodies in malaria-endemic areas, indicating that they 
are not a good tool for screening donors in those areas 
[27, 41]. New epitopes were presented as reasonably good 
markers of asymptomatic or recently exposed popula-
tions [57], but still need to be addressed in blood banks.
In this work, cases were mostly reported from Mexico 
in the 1970s and 1980s (when this country had a higher 
malaria incidence) and in the USA. The incidence of 
TT malaria among people residing in endemic areas is 
unknown. TT malaria cases misclassification is probably 
frequent in populations continuously exposed to malaria 
vectors in the same areas. Furthermore, a proportion of 
the population in malaria-endemic countries presents 
asymptomatic parasitaemia, preventing an accurate 
assessment of whether malaria occurring after transfu-
sion is actually TT malaria [52]. TT malaria surveillance 
is a challenge in active transmission areas, likely reflected 
in under-reporting of cases in Central America and 
Amazon areas. TT malaria can therefore only be distin-
guished from naturally transmitted cases by genotyping 
to demonstrate that the parasite in the transfusion recipi-
ent is identical to the paired transfused blood unit [58]. 
A limitation of this approach is that it fails to detect low-
level Plasmodium clones in the transfused blood.
Transfusion-transmitted malaria prevailed in females 
requiring blood transfusion after gyneco-obstetrical 
complications. A significant number of cases were also 
recorded from the older population, with surgical proce-
dures and complications from neoplasias as the most com-
mon transfusion indications. As expected, whole blood 
and packed RBCs were the most common sources of TT 
malaria in this study, with 94% of the total cases reported. 
Platelets were responsible for 6% of the TT malaria cases. 
Previous reports show that platelets, fresh frozen plasma 
and leukocytes may infrequently transmit malaria [59–
61]. Separate components, such as plasma and platelets, 
may contain merozoites or some RBCs contamination, 
and parasites in such components have been shown to be 
highly sensitive to pathogen reduction measures, such as 
photochemical treatment and long-wavelength ultraviolet 
light (UV) [62]. In Ghana, a randomised, controlled, clini-
cal trial has shown the efficacy and safety of a whole blood 
pathogen reduction using UV and riboflavin (Mirasol Sys-
tem) at preventing TT malaria [63].
Most TT malaria cases were caused by P. malariae. 
Conversely, P. falciparum was the predominant spe-
cies found in the identified donors. This disagreement 
may be due to the fact that many blood units or donor 
samples associated with transfusion P. malariae malaria 
tested negative or positive only by serology. Plasmo-
dium malariae differs from other Plasmodium species 
by its very low levels of parasitaemia, indolent illness 
Table 6 Epidemiological characteristics of  163 blood 
donors identified as  responsible for  transfusion-transmit-





Sex (n = 103; completeness = 63.2%)
 Male 84 81.6
 Female 19 18.4
Age groups (years) (n = 17; completeness = 10.4%)
 17–20 6 35.3
 21–30 9 52.9
 ≥31 2 11.8
History of living or traveling to endemic areas (n = 63; complete-
ness = 38.7%)
 Yes 61 96.8
 No 2 3.2
Probable site of infection (n = 59; completeness = 36.2%)
 Sub-Saharan Africa 36 61.0
  Nigeria 11 18.6
  Ghana 6 10.2
  Liberia 6 10.2
  Other Sub-Saharan countries 13 22.0
 Latin America 9 15.3
  Central American countries 3 5.1
  Brazilian Atlantic Coast 2 3.4
  Mexico 2 3.4
  Colombia 1 1.7
  Venezuela 1 1.7
 Vietnam 5 8.5
 India 2 3.4
 Mediterranean countries 7 11.9
  Greece 4 6.8
  Other Mediterranean countries 3 5.1
History of previous episodes of malaria (n = 33; completeness = 20.2%)
 Yes 11 33.3
 No 22 66.7
Plasmodium species found (n = 130; completeness = 79.8%)
 Plasmodium falciparum 56 43.1
 Plasmodium malariae 36 27.7
 Plasmodium vivax 30 23.1
 Plasmodium ovale 7 5.4
 Mixed P. falciparum–P. vivax 1 0.7
Method(s) evidencing Plasmodium infection (n = 134; complete-
ness = 82.2%)
 IIF alone 66 49.3
 Microscopy plus IIF 45 33.6
 Microscopy alone 11 8.2
 IIF plus PCR 5 3.7
 Microscopy plus IIF plus PCR 3 2.2
 PCR alone 3 2.2
 Bone marrow aspirate examination 
alone
1 0.8
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and extended duration of asymptomatic infection [50, 
64, 65]. Thus, patients generally come to medical atten-
tion when a recrudescence is induced by splenectomy 
performed for reasons unrelated to malaria [66] or when 
malaria is transmitted by transfusion, as observed in 
this study. Plasmodium vivax was the second causative 
agent of TT malaria, mostly related to donors coming 
from Asia and Latin America, whereas P. falciparum 
was associated with donors who lived or visited African 
countries.
Clinical severity of TT malaria is very different in 
endemic and non-endemic countries. In this work, 
lethality was associated with living in a non-endemic 
country. Actually, estimates of lethality rates ranged from 
11% in the USA [67] to 40% in the United Kingdom (UK) 
[68] and 100% in France [69]. Although healthy adults 
living in malaria-endemic areas have some immunity to 
developing clinical malaria, making them able to har-
bour low levels of parasites without developing clini-
cal symptoms, the recipients of blood transfusions are 
predominantly patients with severe co-morbidities who 
are likely to be immunologically compromised. Malaria 
diagnosis in non-endemic countries where local doctors 
are not routinely exposed to the disease constitutes a 
major challenge and requires trained clinical and labora-
tory personnel [5]. In the absence of early diagnosis and 
opportune treatment, TT malaria patients may often 
evolve to poor outcomes. In addition, about 20% of the 
TT malaria patients in this study presented long incuba-
tion periods (more than 3 months), rendering diagnosis 
even more difficult due to a more improbable association 
with transfusion.
Plasmodium falciparum TT malaria was associated 
with higher lethality in comparison with P. malariae and 
P. vivax. Complex systemic disorder triggered by host 
inflammatory responses is present in all types of malaria. 
However, in falciparum malaria there is prominent adhe-
sion and vascular sequestration, leading more frequently 
to severe disease and death [70]. In Latin American coun-
tries where P. vivax predominates, there is an assump-
tion that vivax malaria is more benign and therefore TT 
malaria is not considered an important burden to pub-
lic health [19]. Interestingly, in this work, severity and 
lethality were also observed for P. malariae and P. vivax 
malaria. Especially amongst patients with co-morbidities 
which are characteristic of transfusion recipients, P. vivax 
is associated with severe disease [6, 8].
Complications from neoplasias were associated 
with a higher odd of lethality from TT malaria in com-
parison with other transfusion indications. Patients 
undergoing cancer treatment are commonly under 
immunosuppressive therapy and frequently need blood 
transfusion due to anaemia episodes from chemotherapy. 
Transfusion-transmitted malaria in patients with neo-
plastic diseases increases the risk of severe clinical 
picture and fulminant evolution, regardless of the Plas-
modium species [61, 71–73]. In cancer patients, even 
those at early stages, several coagulation abnormalities 
lead to an increased tendency to haemostatic dysfunction 
[74], directly influencing malaria pathogenesis, includ-
ing disseminated intravascular coagulation and cerebral 
malaria [75]. Baseline coagulation disorders triggered 
by neoplastic disease may play a key role in developing 
malaria complications. Considering that TT malaria in a 
patient with cancer (and possibly other severe co-mor-
bidities) is always a life-threatening condition, malaria 
diagnosis must always be considered in patients with a 
post-transfusion febrile illness. In these cases, however, 
it is difficult to define the immediate cause of death to 
malaria rather than the underlying condition.
Conclusions
The burden imposed by TT malaria in most countries of 
Latin America with endemic malaria remains a critical 
knowledge gap. Without this information, it is impossi-
ble to estimate whether pre-transfusion screening within 
endemic settings is a cost-effective option for preven-
tion of TT malaria. Furthermore, there is no screening 
method available that is practical, affordable and sensi-
tive enough for use by blood banks in American coun-
tries where P. vivax, a species associated with relapsing 
episodes and low-level parasitaemia, contributes greatly 
to transmission. Most available malaria tests, even those 
based on DNA amplification, may still have limited sensi-
tivity to detect very low levels of parasites (enough to lead 
to TT malaria), and there is no evidence-based guidance 
to indicate which malaria screening methods are effective 
for use by transfusion services in malaria-endemic coun-
tries. It is difficult to estimate the incidence of TT malaria 
among people residing in endemic areas, especially due 
to TT malaria cases misclassification in populations 
continuously exposed to vectors, which may lead to a 
serious underestimation of TT malaria cases. Lethality 
associated with TT malaria is not negligible, and corre-
lated with living in non-endemic countries when P. fal-
ciparum was the causative agent and neoplastic diseases 
were the transfusion indication. In the current context of 
malaria transmission in Latin America, uncommon ways 
of transmission regain attention, such as TT malaria, a 
potential vehicle for parasite re-introduction in areas 
moving towards elimination. In the absence of a realis-
tic estimate of TT malaria burden, a possible cost benefit 
analysis of molecular screening or other more sensitive 
tests in blood donor candidates compared to TT malaria 
healthcare-associated costs remains a major gap in the 
literature (Additional file 1).
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